noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

EERE - Office of Energy Efficiency[...]

U.S. Department of Energy Kicks Off Nationwide Battery Workforce[...]
U.S. Department of Defense

Readout of Secretary of Defense Lloyd J. Austin III's Call With Israeli[...]
City of Manistee, MI

CHILL Grant Application

Healthcare

ARS Pharmaceuticals Inc.

09/23/2024 | Press release | Distributed by Public on 09/23/2024 06:07

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

Read this content

Click here to read the original version at the source's official website. The text of this article is not available at the moment.

Sharing and Personal Tools

Please select the service you want to use:

Smartlinks | ARS Pharmaceuticals Inc. | News | Health | Securities Issuers | Biotechnology and Medical Research Companies | NYSE American | NYSE ARCA Equities | Nasdaq Global Market | Cboe BZX Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | FINRA Alternative Display Facility (ADF) | Nasdaq BX | Nasdaq PSX | NYSE Chicago

Back